Fig. 2

DCLK1 reduces the sensitivity of TNBC cells to chemotherapeutics. a CCK8 assays showing a higher nanomolar IC50 by doxorubicin (left) and cisplatin (right) in DCLK1-overexperssing cells than the corresponding control (doxorubicin, 1.83–9.92 μM; cisplatin, 23.96–45.95 μM). b CCK8 assays showing a lower nanomolar IC50 by doxorubicin (left) and cisplatin (right) in DCLK1-knockout cells than the corresponding control (doxorubicin, 16.48–6.69 μM; cisplatin, 25.3–13.3 μM). c Annexin V analysis was used to detect the effects of cisplatin on apoptosis of BT549-control cells and BT549-DCLK1-KO cells. d GSE103668 dataset analysis of the association between DCLK1 expressions and the efficacy of neoadjuvant chemotherapy in TNBC. e qPCR analysis showing the increased expression of DCLK1 in TNBC cells after cisplatin treatment. f Western blotting disclosing the increased expression of CSC-related markers in TNBC cells after cisplatin treatment